Quantitative Polymerase Chain Reaction Profiling of Immunomarkers in Rejecting Kidney Allografts for Predicting Response to Steroid Treatment (original) (raw)

[Immunosuppressive agents in pediatric renal transplantation]

Revue médicale de Bruxelles

Advances in immunosuppressive therapy over the past decade have led to dramatic improvements of patient and graft survival. The immunosuppression that is used is constantly evolving. The goal remains to find the best combination that will optimize long-term graft survival, while minimizing the adverse effects. It is likely that in the near future the results will even be improved further by the development of new medications with a better therapeutic index and the induction of transplant tolerance.

[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant]

La Presse Médicale

Reçu le xxx Accepté le xxx s Summary Statins in patients with kidney failure Efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplants Background > Chronic kidney disease (CKD) is extremely common in adults, although often undiagnosed and thus untreated. Cardiovascular disease is the leading cause of death among patients with CKD and reducing its risk in this population is an important priority. Dyslipidemia is almost always present when proteinuria is above 3 gr/24 hours. Roughly two thirds of all patients with end-stage renal failure and kidney transplants suffer from dyslipidemia and should receive lipidlowering therapy, as suggested by recent Afssaps (French drug agency) and NKF-K/DOQI (National Kidney Foundation-Kidney Disease Outcomes Quality Initiative) guidelines. We reviewed recent studies on efficacy, tolerability and prescription recommendations of statins in CKD and renal transplant patients. Methods > We searched Medline, the international medical database, to conduct a systematic review of the literature on the efficacy and tolerability of statins in CKD and renal transplant patients and on specific recommendations for dosage adjustments in this population. Results > The efficacy of statins in decreasing total cholesterol and LDL-cholesterol levels in dialysis and renal transplant patients is simi-s Résumé tome 35 > n°2 > février 2006 > cahier 1 Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C lar to that in the general population. On the other hand, large-scale randomized clinical trials among CKD (4D) and renal transplant (ALERT) patients do not demonstrate that statins significantly decrease rates of cardiovascular disease. They have a beneficial effect on proteinuria and lower the rate of kidney function deterioration in patients with dyslipidemia. Early introduction of a statin in transplant patients did not lead to improved kidney function or prevent loss of the graft. Although most statins are not excreted by the kidneys, the dosage of some must be adapted in CKD patients because of pharmacokinetic modifications induced by renal impairment. Conclusion > Statins at appropriately adapted doses have the same efficacy in CKD patients as in subjects with normal kidney function, and tolerance is not a problem. Their effectiveness in cardiovascular prevention in this population has not been demonstrated to date. Results about statin-induced kidney protection are encouraging but further and more specific studies are needed. Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C. Prescription des statines en cas d'insuffisance rénale. Efficacité, tolérance et maniement chez le patient insuffisant rénal et chez le patient transplanté rénal.

Statins in patients with kidney failure - Efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplants

2006

Reçu le xxx Accepté le xxx s Summary Statins in patients with kidney failure Efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplants Background > Chronic kidney disease (CKD) is extremely common in adults, although often undiagnosed and thus untreated. Cardiovascular disease is the leading cause of death among patients with CKD and reducing its risk in this population is an important priority. Dyslipidemia is almost always present when proteinuria is above 3 gr/24 hours. Roughly two thirds of all patients with end-stage renal failure and kidney transplants suffer from dyslipidemia and should receive lipidlowering therapy, as suggested by recent Afssaps (French drug agency) and NKF-K/DOQI (National Kidney Foundation-Kidney Disease Outcomes Quality Initiative) guidelines. We reviewed recent studies on efficacy, tolerability and prescription recommendations of statins in CKD and renal transplant patients. Methods > We searched Medline, the international medical database, to conduct a systematic review of the literature on the efficacy and tolerability of statins in CKD and renal transplant patients and on specific recommendations for dosage adjustments in this population. Results > The efficacy of statins in decreasing total cholesterol and LDL-cholesterol levels in dialysis and renal transplant patients is simi-s Résumé tome 35 > n°2 > février 2006 > cahier 1 Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C lar to that in the general population. On the other hand, large-scale randomized clinical trials among CKD (4D) and renal transplant (ALERT) patients do not demonstrate that statins significantly decrease rates of cardiovascular disease. They have a beneficial effect on proteinuria and lower the rate of kidney function deterioration in patients with dyslipidemia. Early introduction of a statin in transplant patients did not lead to improved kidney function or prevent loss of the graft. Although most statins are not excreted by the kidneys, the dosage of some must be adapted in CKD patients because of pharmacokinetic modifications induced by renal impairment. Conclusion > Statins at appropriately adapted doses have the same efficacy in CKD patients as in subjects with normal kidney function, and tolerance is not a problem. Their effectiveness in cardiovascular prevention in this population has not been demonstrated to date. Results about statin-induced kidney protection are encouraging but further and more specific studies are needed. Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C. Prescription des statines en cas d'insuffisance rénale. Efficacité, tolérance et maniement chez le patient insuffisant rénal et chez le patient transplanté rénal.

Genetics and epigenetics at the service of kidney diseases

Batna journal of medical sciences, 2015

Il s'agit d'un article en libre accès distribué selon les termes de la licence Creative Commons Attribution International License (CC BY 4.0), qui autorise une utilisation, une distribution et une reproduction sans restriction sur tout support ou format, à condition que l'auteur original et la revue soient dûment crédités. _____________________________________ RÉSUMÉ La maladie rénale chronique augmente le risque de morbi-mortalité. Le diagnostic est aisé mais rétrospectif, les facteurs de risques sont codifiés et ainsi que les principales cibles thérapeutiques. L'épigénome, interface entre le génome et le phénotype, semble attiser l'attention de la médecine moderne pour établir de nouvelles méthodes diagnostiques précoces et adopter une prise en charge personnalisée pour une meilleure efficience.